Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) have entered into a strategic manufacturing partnership for biosimilars, as announced on July 14, 2026. Under the agreement, OneSource will serve as a manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics facility in Bangalore, India. The collaboration combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing capabilities to support Formycon's biosimilar programs for global markets.
Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies." Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, added: "We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide."
The partnership underscores the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model, which OneSource is positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
Formycon's FYB4Growth strategy is based on four pillars: geographic diversification, smart portfolio strategy, excellence and innovation, and consistent cost efficiency. This partnership aligns with the cost efficiency pillar by leveraging OneSource's manufacturing capabilities. Formycon already has three biosimilars on the market (FYB201/ranibizumab, FYB202/ustekinumab, FYB203/aflibercept) and four pipeline candidates, including FYB206/pembrolizumab and FYB208/dupilumab. The company is headquartered in Munich and listed in the Prime Standard of the Frankfurt Stock Exchange. More information can be found at https://www.formycon.com/ and https://www.fyb4growth.com.
OneSource Specialty Pharma is a pure-play global CDMO focusing on complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies. With five state-of-the-art manufacturing facilities approved by global regulatory authorities and a team of over 1,600 professionals, OneSource provides end-to-end solutions. More details are available at www.onesourcecdmo.com.
Biosimilars are successor products to biopharmaceutical drugs whose market exclusivity has expired. They are approved in highly regulated markets such as the EU, USA, Canada, Japan, and Australia under strict regulatory procedures. Biosimilars create competition, giving more patients access to biopharmaceutical therapies while reducing healthcare system costs. Global sales of biosimilars currently amount to around 21 billion US dollars, with analysts projecting a rise to over 74 billion US dollars by 2030. This partnership is poised to contribute to that growth by expanding manufacturing capacity and cost-efficiency.
